G Lemesle1,2,3, G Schurtz1, C Bauters1,2,3, M Hamon4,5. 1. Centre Hospitalier Régional et Universitaire de Lille, Lille, France. 2. Inserm U744, Institut Pasteur de Lille, Lille, France. 3. Faculté de Médecine de l'Université de Lille, Lille, France. 4. Centre Hospitalier Universitaire de Caen, Caen, France. 5. Faculté de Médecine de Caen, Caen, France.
Abstract
BACKGROUND: Ticagrelor and prasugrel have shown superiority over clopidogrel. However, it remains unclear if one is superior to another regarding on-treatment platelet reactivity. OBJECTIVES: To compare the impact of ticagrelor and prasugrel on high on-treatment platelet reactivity (HTPR). METHODS: The PubMed and Cochrane databases were searched for eligible studies in December 2014. Studies were eligible if they compared ticagrelor and prasugrel regarding high on-treatment platelet reactivity (HTPR). Pooled estimates were calculated by using a random-effects model with 95% confidence intervals. RESULTS: We included 14 studies and 1822 patients: 805 and 1017 in the ticagrelor and prasugrel groups, respectively. The rate of HTPR was significantly lower in the ticagrelor group: 1.5% vs. 9.8% (RR = 0.27 [0.14-0.50]). The pre-specified analysis focusing on randomized trials (n = 10) showed consistent results (RR = 0.27 [0.12-0.60]). CONCLUSION: Our results suggest that ticagrelor allows a higher platelet reactivity inhibition as compared with prasugrel and leads to a further decrease in the rate of HTPR.
BACKGROUND:Ticagrelor and prasugrel have shown superiority over clopidogrel. However, it remains unclear if one is superior to another regarding on-treatment platelet reactivity. OBJECTIVES: To compare the impact of ticagrelor and prasugrel on high on-treatment platelet reactivity (HTPR). METHODS: The PubMed and Cochrane databases were searched for eligible studies in December 2014. Studies were eligible if they compared ticagrelor and prasugrel regarding high on-treatment platelet reactivity (HTPR). Pooled estimates were calculated by using a random-effects model with 95% confidence intervals. RESULTS: We included 14 studies and 1822 patients: 805 and 1017 in the ticagrelor and prasugrel groups, respectively. The rate of HTPR was significantly lower in the ticagrelor group: 1.5% vs. 9.8% (RR = 0.27 [0.14-0.50]). The pre-specified analysis focusing on randomized trials (n = 10) showed consistent results (RR = 0.27 [0.12-0.60]). CONCLUSION: Our results suggest that ticagrelor allows a higher platelet reactivity inhibition as compared with prasugrel and leads to a further decrease in the rate of HTPR.
Authors: Francesco Franchi; Fabiana Rollini; Jose Rivas; Andrea Rivas; Malhar Agarwal; Maryuri Briceno; Mustafa Wali; Ahmed Nawaz; Gabriel Silva; Zubair Shaikh; Naji Maailiki; Latonya Been; Andres M Pineda; Siva Suryadevara; Daniel Soffer; Martin M Zenni; Theodore A Bass; Dominick J Angiolillo Journal: JACC Basic Transl Sci Date: 2020-03-25
Authors: Patricia P Wadowski; Joseph Pultar; Constantin Weikert; Beate Eichelberger; Benjamin Panzer; Kurt Huber; Irene M Lang; Renate Koppensteiner; Simon Panzer; Thomas Gremmel Journal: Res Pract Thromb Haemost Date: 2019-05-22
Authors: Marco Ranucci; Tommaso Aloisio; Umberto Di Dedda; Lorenzo Menicanti; Carlo de Vincentiis; Ekaterina Baryshnikova Journal: PLoS One Date: 2019-11-27 Impact factor: 3.240
Authors: Małgorzata Ostrowska; Jacek Kubica; Piotr Adamski; Aldona Kubica; Ceren Eyileten; Marek Postula; Aurel Toma; Christian Hengstenberg; Jolanta M Siller-Matula Journal: Front Cardiovasc Med Date: 2019-12-03